The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and ...

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

Timothy Mullett, MD, leaned toward his computer screen as he spoke, drowning out the sounds of the busy coffee shop behind him to get his message across.

Goshen Center for Cancer Care is recognizing the completion of 50 procedures utilizing cutting-edge robotic technology to provide a less invasive option to biopsy lung lesions. The Galaxy System is a ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

Panelists discuss how biomarker testing is currently utilized in the management of patients with small cell lung cancer (SCLC), including its timing within the treatment journey, while also exploring ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.

All women should start mammograms at age 40 to screen for breast cancer, regardless of family history. Sponsored by Virginia Mason Franciscan Health.

The narrative spans four generations, highlighting the hereditary nature of breast cancer and its impact on family dynamics.